<DOC>
	<DOC>NCT02195141</DOC>
	<brief_summary>Pathological complete response, (pCR) correlates with a favorable overall prognosis in locally advanced rectal cancer patients underwent preoperative chemoradiation, so obtaining a pCR might be beneficial. The aim of the study is to investigate safety and efficacy of preoperative SIB-IMRT(56Gy) combine with capecitabine. primary endpoint is pathological complete remission rate.</brief_summary>
	<brief_title>Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>histopathologically confirmed rectal adenocarcinoma with an inferior border within 15 cm of the anal verge the tumor has to have evidence of T3 or T4 disease on Magnetic Resonance Imaging (MRI) or endoluminal ultrasound metastatic disease Eastern Cooperative Oncology Group (ECOG) performance status &gt; 3 patients not deemed fit for radiotherapy, capecitabine or surgery pregnant or lactating patients women with child bearing potential who lack effective contraception patients below 18 years old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Preoperative Chemoradiotherapy</keyword>
	<keyword>Locally Advanced Rectal Cancer</keyword>
	<keyword>boost</keyword>
	<keyword>IMRT</keyword>
</DOC>